Meadow Creek Investment Management LLC grew its position in Eli Lilly And Co (NYSE:LLY) by 7.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 49,296 shares of the company’s stock after buying an additional 3,232 shares during the period. Meadow Creek Investment Management LLC’s holdings in Eli Lilly And Co were worth $5,461,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Renaissance Technologies LLC lifted its stake in shares of Eli Lilly And Co by 218.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,308,601 shares of the company’s stock valued at $255,770,000 after purchasing an additional 1,583,947 shares during the period. Thoroughbred Financial Services LLC boosted its stake in Eli Lilly And Co by 11,124.4% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 854,403 shares of the company’s stock worth $85,440,000 after acquiring an additional 846,791 shares during the last quarter. Bessemer Group Inc. boosted its stake in Eli Lilly And Co by 2,354.5% during the 2nd quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock worth $63,096,000 after acquiring an additional 546,307 shares during the last quarter. Prudential Financial Inc. grew its holdings in Eli Lilly And Co by 38.4% during the second quarter. Prudential Financial Inc. now owns 1,313,910 shares of the company’s stock valued at $145,568,000 after purchasing an additional 364,717 shares during the period. Finally, Canada Pension Plan Investment Board grew its holdings in Eli Lilly And Co by 76.9% during the second quarter. Canada Pension Plan Investment Board now owns 803,520 shares of the company’s stock valued at $89,022,000 after purchasing an additional 349,179 shares during the period. 76.78% of the stock is owned by institutional investors.
In other news, SVP Stephen F. Fry sold 9,452 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $115.00, for a total value of $1,086,980.00. Following the completion of the transaction, the senior vice president now owns 100,211 shares in the company, valued at approximately $11,524,265. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the completion of the transaction, the senior vice president now owns 38,306 shares of the company’s stock, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.
LLY has been the topic of several analyst reports. Goldman Sachs Group initiated coverage on shares of Eli Lilly And Co in a report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price on the stock. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Bank of America raised their price target on Eli Lilly And Co from $118.00 to $120.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $122.93.
Shares of LLY traded up $0.01 during midday trading on Wednesday, hitting $111.11. The stock had a trading volume of 1,172,622 shares, compared to its average volume of 3,141,462. The firm has a market cap of $107.23 billion, a price-to-earnings ratio of 20.02, a price-to-earnings-growth ratio of 1.96 and a beta of 0.16. The company has a 50 day simple moving average of $111.46 and a two-hundred day simple moving average of $117.00. Eli Lilly And Co has a twelve month low of $104.17 and a twelve month high of $132.13. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.13 and a quick ratio of 0.87.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.05. The company had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. Eli Lilly And Co’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.48 earnings per share. Analysts forecast that Eli Lilly And Co will post 5.72 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were given a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a yield of 2.32%. The ex-dividend date was Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 46.49%.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Why do commodities matter?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.